英国风湿病学会生物制剂注册登记：六年回顾 - Suppr

Suppr

超能文献

The British Society for Rheumatology Biologics Register: 6 years on.

作者信息

Hyrich K L, Watson K D, Isenberg D A, Symmons D P M

出版信息

Rheumatology (Oxford). 2008 Oct;47(10):1441-3. doi: 10.1093/rheumatology/ken242. Epub 2008 Jul 1.

DOI:10.1093/rheumatology/ken242

PMID:18596052

Abstract

摘要

相似文献

The British Society for Rheumatology Biologics Register: 6 years on.英国风湿病学会生物制剂注册登记：六年回顾

Rheumatology (Oxford). 2008 Oct;47(10):1441-3. doi: 10.1093/rheumatology/ken242. Epub 2008 Jul 1.

Comparative overview of safety of the biologics in rheumatoid arthritis.类风湿关节炎生物制剂安全性的比较概述

J Rheumatol Suppl. 2009 Jun;82:25-32. doi: 10.3899/jrheum.090128.

MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.监测网络：一项意大利多中心观察性研究，旨在评估生物制剂在实际风湿病治疗中的风险/获益情况。

Reumatismo. 2009 Apr-Jun;61(2):132-9.

Joint approach.联合方法。

Minn Med. 2009 Sep;92(9):22-5.

Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.使用肿瘤坏死因子α抑制剂治疗的类风湿关节炎患者发生耶氏肺孢子菌肺炎的风险：来自英国风湿病学会类风湿关节炎生物制剂注册研究的结果

Rheumatology (Oxford). 2016 Jul;55(7):1336-7. doi: 10.1093/rheumatology/kew200. Epub 2016 Apr 26.

[Recommendations of the German Society of Rheumatology for therapy with tumor necrosis factor inhibitors. Pharmacotherapy Committee of the German Society of Rheumatology].[德国风湿病学会关于肿瘤坏死因子抑制剂治疗的建议。德国风湿病学会药物治疗委员会]

Z Rheumatol. 2000 Aug;59(4):291-2.

Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.评论：类风湿关节炎管理中肿瘤坏死因子拮抗剂成本效益的建模：来自英国风湿病学会生物制剂注册库的结果

Rheumatology (Oxford). 2008 Jul;47(7):1106-7; author reply 1107. doi: 10.1093/rheumatology/ken105. Epub 2008 Mar 7.

Use of biologic agents in rheumatoid arthritis: introduction.生物制剂在类风湿关节炎中的应用：引言

Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv3-4. doi: 10.1093/rheumatology/ker239.

BSR Biologics Registry.英国风湿病学会生物制剂注册库

Rheumatology (Oxford). 2004 Dec;43(12):1463-4. doi: 10.1093/rheumatology/keh356. Epub 2004 Aug 24.

[Safety of biologic therapy - results from the German biologics register RABBIT].[生物治疗的安全性——来自德国生物制剂登记处RABBIT的结果]

Dtsch Med Wochenschr. 2014 Sep;139(37):1817-20. doi: 10.1055/s-0034-1370252. Epub 2014 Sep 2.

引用本文的文献

Potential impact of European Medicines Agency measures to minimize risk of serious side effects on JAKi prescribing and utilization in the UK.欧洲药品管理局为将严重副作用风险降至最低所采取措施对英国JAKi类药物处方及使用的潜在影响。

Rheumatology (Oxford). 2025 Mar 1;64(3):1453-1458. doi: 10.1093/rheumatology/keae279.

Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA.1024例类风湿关节炎患者从原研依那西普转换为依那西普生物类似药后的结局：英国风湿病学会生物制剂注册登记处类风湿关节炎匹配分析

Rheumatology (Oxford). 2024 Aug 1;63(8):2082-2092. doi: 10.1093/rheumatology/kead470.

Socioeconomic deprivation is associated with reduced response and lower treatment persistence with TNF inhibitors in rheumatoid arthritis.社会经济剥夺与类风湿关节炎中 TNF 抑制剂的反应降低和治疗持久性降低有关。

Rheumatology (Oxford). 2024 Mar 1;63(3):648-656. doi: 10.1093/rheumatology/kead261.

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA.依那西普原研药与依那西普生物类似药治疗类风湿关节炎作为一线生物制剂的比较：来自 BSRBR-RA 的结果。

Rheumatology (Oxford). 2023 Dec 1;62(12):3849-3857. doi: 10.1093/rheumatology/kead127.

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis.生物制剂序贯治疗与靶向治疗药物在类风湿关节炎中的疗效。

Rheumatology (Oxford). 2022 Nov 28;61(12):4678-4686. doi: 10.1093/rheumatology/keac190.

Methodological considerations when analysing and interpreting real-world data.分析和解释真实世界数据时的方法学考虑。

Rheumatology (Oxford). 2020 Jan 1;59(1):14-25. doi: 10.1093/rheumatology/kez320.

Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey.生物类似药在风湿病学中有效药物警戒系统的障碍：一项拉丁美洲调查。

Pharmacoepidemiol Drug Saf. 2019 Aug;28(8):1035-1044. doi: 10.1002/pds.4785. Epub 2019 May 30.

Interpretation of DAS28 and its components in the assessment of inflammatory and non-inflammatory aspects of rheumatoid arthritis.在类风湿关节炎炎症和非炎症方面评估中DAS28及其组成部分的解读

BMC Rheumatol. 2018 Mar 23;2:8. doi: 10.1186/s41927-018-0016-9. eCollection 2018.

: a home for all rheumatology research within the BMC Series.BMC系列内所有风湿病学研究的家园。

BMC Rheumatol. 2017 Nov 28;1:1. doi: 10.1186/s41927-017-0006-3. eCollection 2017.

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.类风湿关节炎中的生物难治性疾病：来自英国风湿病学会类风湿关节炎生物制剂注册处的结果。

Ann Rheum Dis. 2018 Oct;77(10):1405-1412. doi: 10.1136/annrheumdis-2018-213378. Epub 2018 Jul 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验